Skip to content

Study · Animal study (in vivo) · mouse · 2016

4 results

Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.

Ming W, Lu G, Xin S, Huanyu L, Yinghao J, Xiaoying L, Chengming X, Banjun R, Li W, Zifan L

Biochemical and biophysical research communications26 May 2016Cited by 73 (Europe PMC)

PMID27237975 (opens in a new tab)DOI10.1016/j.bbrc.2016.05.135 (opens in a new tab)PepBankPUB-27237975
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, MOTS‑c treatment significantly alleviated bone loss on micro-CT examination.

    In plain wordsIn mice with ovary removal, MOTS‑c treatment reduced bone loss.

    Peptide
    MOTS-c
    Outcome
    DecreaseBone loss by micro-CT
    Study

    mousen: not reported in source

    Ovariectomy-induced osteoporosis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mg/kg once a day · 12 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results showed that MOTS-c treatment significantly alleviated bone loss, as determined by micro-CT examination.
    1 context sentence
    Summary · context
    After ovary removal, the mice were injected with MOTS-c at a dose of 5 mg/kg once a day for 12 weeks.
  2. 02LabIn vitro (cells)Mechanism

    MOTS‑c remarkably inhibited RANKL-induced osteoclast differentiation.

    In plain wordsIn lab tests, MOTS‑c strongly reduced the formation of bone-resorbing osteoclasts.

    Peptide
    MOTS-c
    Outcome
    DecreaseRANKL-induced osteoclast differentiation
    Study

    n: not reported in source

    RANKL-induced osteoclast differentiation
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, we found that the receptor activator of nuclear factor-κB ligand (RANKL) induced osteoclast differentiation was remarkably inhibited by MOTS-c.
  3. 03LabIn vitro (cells)Mechanism

    MOTS‑c increased phosphorylated AMPK levels.

    In plain wordsIn lab tests, MOTS‑c raised the active form of the enzyme AMPK.

    Peptide
    MOTS-c
    Outcome
    IncreasePhosphorylated AMPK level
    Study

    n: not reported in source

    Osteoclast differentiation experiments
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c increased phosphorylated AMPK levels, and compound C, an AMPK inhibitor, could partially abrogate the effects of the MOTS-c on osteoclastogenesis.
  4. 04LabIn vitro (cells)Mechanism

    The AMPK inhibitor compound C partially abrogated the effects of MOTS‑c on osteoclastogenesis.

    In plain wordsIn lab tests, blocking AMPK partly removed the effect of MOTS‑c on osteoclast formation.

    Peptide
    MOTS-c
    Outcome
    Not applicableMOTS-c effect on osteoclastogenesis with AMPK inhibitor compound C
    Study

    n: not reported in source

    Osteoclast differentiation experiments
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    compound C, an AMPK inhibitor, could partially abrogate the effects of the MOTS-c on osteoclastogenesis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.